Drug Trial Radar · NCT07620938
Clinical Study of TJ0113 Capsule in the Treatment of Patients With Sarcopenia
Last checked: Nov 19, 2026Latest source record: Aug 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
204
Planned (sponsor's estimate)
Start
Jun 12, 2026
Primary completion
Aug 22, 2027
Study completion Oct 22, 2027
Sponsor
- Lead sponsor
- Hangzhou PhecdaMed Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jun 2, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a randomized, double-blind, multicenter, placebo parallel-controlled Phase II clinical study designed to evaluate the clinical efficacy and safety of TJ0113 Capsule in patients with sarcopenia. The entire study plans to enroll 204 participants with sarcopenia. Eligible participants will be stratified by age (\< 70 years or ≥ 70 years to ≤ 80 years or \> 80 years) and block-randomized in a 1:1:1:1 ratio into 4 groups (TJ0113 Capsule 100 mg dose group; TJ0113 Capsule 200 mg dose group; TJ0113 Capsule 400 mg dose group; placebo group), with 51 participants per group. Participants in the placebo group will then be re-randomized in a 1:1:1 ratio to the respective dose groups (100 mg, 200 mg, and 400 mg). After randomization, study participants will receive continuous oral administration for 26 weeks with efficacy and safety evaluations, followed by a 1-week follow-up period after the end of treatment.
Conditions
- Sarcopenia
Interventions
TJ0113Drug
100mg or 200 mg or 400 mg Capsule, Once Daily
TJ0113Drug
100mg or 200 mg or 400 mg Capsule, Once Daily
TJ0113Drug
100mg or 200 mg or 400 mg Capsule, Once Daily
PlaceboDrug
Capsule, Once Daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in gait speed on the 400-meter Walk Test at Week 26Time frame: After 26 weeks of treatment
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.